Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 15,256

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Open access
Wanchoo, Rimda, Karam, Sabine, Uppal, Nupur N., Barta, Valerie S., Deray, Gilbert, Devoe, Craig, Launay-Vacher, Vincent, Jhaveri, Kenar D., on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors·2017·American Journal of Nephrology
DOI 10.1159/000455014
Open this paper in CoChat — free account

Abstract

Background: Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers. Summary: In order to provide an extensive overview of the renal toxicities induced by these agents, a Medline search was conducted of published literature related to ipilimumab-, pembrolizumab-, and nivolumab-induced kidney toxicity. In addition, primary data from the initial clinical trials of these agents and the FDA adverse reporting system database were also reviewed to determine renal adverse events. Acute interstitial nephritis (AIN), podocytopathy, and hyponatremia were toxicities caused by ipilimumab. The main adverse effect associated with both the PD-1 inhibitors was AIN. The onset of kidney injury seen with PD-1 inhibitors is usually late (3-10 months) compared to CTLA-4 antagonists related renal injury, which happens earlier (2-3 months). PD-1 as opposed to CTLA-4 inhibitors has been associated with kidney rejection in transplantation. Steroids appear to be effective in treating the immune-related adverse effects noted with these agents. Key Message: Although initially thought to be rare, the incidence rates of renal toxicities might be higher (9.9-29%) as identified by recent studies. As a result, obtaining knowledge about renal toxicities of immune checkpoint inhibitors is extremely important.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000455014

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 35

  1. 10.1016/j.coi.2015.11.001 · DOI
  2. 10.1016/S0065-2776(06)90001-7 · DOI · Paper page
  3. 10.1177/1060028015586218 · DOI
  4. 10.18632/oncotarget.2980 · DOI
  5. 10.1007/s11912-012-0284-2 · DOI
  6. 10.1016/j.kint.2016.04.008 · DOI · Paper page
  7. 10.1371/journal.pone.0053745 · DOI · Paper page
  8. 10.1097/MJT.0b013e3182a32ddc · DOI
  9. 10.1093/annonc/mdq013 · DOI · Paper page
  10. 10.1056/NEJMc0904283 · DOI · Paper page
  11. 10.1200/JCO.2011.41.4359 · DOI
  12. 10.1007/s10637-014-0092-7 · DOI
  13. 10.1016/j.kint.2015.11.028 · DOI
  14. 10.1007/s12032-010-9794-7 · DOI
  15. 10.1016/j.clineuro.2014.06.011 · DOI
  16. 10.1158/1078-0432.CCR-14-2607 · DOI · Paper page
  17. 10.1016/S0140-6736(14)60958-2 · DOI · Paper page
  18. 10.1016/S1470-2045(15)00083-2 · DOI · Paper page
  19. 10.1158/2326-6066.CIR-13-0146 · DOI
  20. 10.1053/j.ajkd.2016.02.057 · DOI · Paper page
  21. 10.1016/j.ctrv.2016.02.003 · DOI · Paper page
  22. 10.1200/JCO.2014.58.3708 · DOI · Paper page
  23. 10.1200/JCO.2013.53.0105 · DOI · Paper page
  24. 10.1016/S1470-2045(15)70076-8 · DOI · Paper page
  25. 10.1093/ckj/sfw024 · DOI
  26. 10.1007/s11523-016-0426-9 · DOI
  27. 10.4049/jimmunol.1400497 · DOI
  28. 10.4049/jimmunol.179.11.7466 · DOI
  29. 10.1093/ndt/gfl818 · DOI
  30. 10.1681/ASN.2006050418 · DOI · Paper page
  31. 10.1200/JCO.2013.49.2314 · DOI
  32. 10.1056/NEJMc1509268 · DOI · Paper page
  33. 10.1111/ajt.13711 · DOI
  34. 10.1093/annonc/mdw130 · DOI
  35. 10.1111/ajt.13786 · DOI

Cited by

Items 401–500 of 647

Metadata

Authors
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors
Venue
American Journal of Nephrology
Publisher
S. Karger AG
Published
2017
Volume
45
Issue
2
Pages
160-169
ISSN
  • 0250-8095 (ISSN-L)
  • 1421-9670
DOI
10.1159/000455014
OpenAlex
W2572174216
Cited by
15,256
References
14
FWCI
180.98
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.